Mineralys Therapeutics, Inc. (MLYS)
29.04
+3.47
(+13.57%)
USD |
NASDAQ |
Sep 02, 16:00
29.47
+0.43
(+1.48%)
After-Hours: 05:35
Mineralys Therapeutics Research and Development Expense (Annual) : 132.01M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 132.01M |
| December 31, 2024 | 168.58M |
| December 31, 2023 | 70.36M |
| Date | Value |
|---|---|
| December 31, 2022 | 26.25M |
| December 31, 2021 | 16.31M |
| December 31, 2020 | 2.411M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| MapLight Therapeutics, Inc. | 138.35M |
| Evommune, Inc. | 74.04M |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |
| Oncolytics Biotech, Inc. | 13.31M |
| Sangamo Therapeutics, Inc. | 112.67M |